Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
October 23, 2023 08:30 ET
|
Qualigen Therapeutics, Inc.
Poster Includes Preclinical Data on Pan-RAS Compounds Demonstrating Inhibition in Breast Cancer Models CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:30 ET
|
Qualigen Therapeutics, Inc.
Q3 2022 FastPack ® sales increased approximately 25% year-over-yearCompany continues to execute on and advance core therapeutic programs CARLSBAD, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Qualigen...
Qualigen Therapeutics to Present at LD Micro Main Event XV
October 18, 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack®
April 05, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...